10x Genomics, Inc. (TXG) stock analysis
In our weekly check, 10x Genomics, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 11 pass, warnings: 1, red flags: 9.
About 10x Genomics, Inc.
10x Genomics, Inc. is a Healthcare company (Health Information Services) based in the United States, listed on NASDAQ as TXG.
What our checks show for TXG
Red flags
- The gross margin fell by 13 points, to 71.9%: costs are rising faster than prices.
- Weak EPS forecast
- Earnings per share fell 29.1% a year over the last 3 years.
- The company is losing money: the net margin is -10.8%.
- The price swings a lot: 76.3% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 96% from a peak. Would you have held through that?
- Beta 2.03: the stock usually moves more than the market, both up and down.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Pay in shares equals 103% of free cash flow: it dilutes shareholders.
Warning signs
- The stock is still below its previous peak.
Strengths
- Debt is low: 0.09x equity.
- The net margin rose by 1 points over 5 years, to -10.8%.
- Operating cash flow is 1.49x net profit: the profit arrives as real cash.
- Analysts expect the net margin to improve by 4.5 points from today's -10.8%.
- Free cash flow is 15.2% of revenue: cash for dividends, buybacks or growth.
- Actively traded: about 3.4 million shares a day.
Next earnings report: 2027-02-11
Similar companies
IMVT · ORKA · KOD · TWST · ARWR · AXSM
Questions
What grade does 10x Genomics, Inc. (TXG) have?
In our weekly check, 10x Genomics, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 11 pass, warnings: 1, red flags: 9. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of TXG stock?
This week's biggest flags for 10x Genomics, Inc.: Gross margin falling, Weak EPS forecast, Weak EPS growth. In total 10 of 21 checks show a warning or a red flag.
What does 10x Genomics, Inc. do?
10x Genomics, Inc. is a Healthcare company (Health Information Services) based in the United States, listed on NASDAQ as TXG.
When does 10x Genomics, Inc. report earnings next?
The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis